October 28, 2020
1 min read

IND application approved for study of allergic conjunctivitis treatment

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has approved an investigational new drug application for the evaluation of VSJ-110, a cystic fibrosis transmembrane conductance regulator activator, for treating allergic conjunctivitis, according to a press release.

A phase 2 study will evaluate the anti-inflammatory effects of the CFTR activator, under development by Vanda Pharmaceuticals, in an ocular allergic challenge model and will investigate “the prosecretory effects using standard tear production assessments,” the release said.

“This is an exciting milestone in the course of our collaboration with University of California, San Francisco (UCSF) and Dr. Alan Verkman towards the development of human therapeutics targeting the cystic fibrosis transmembrane conductance regulator,” Mihael H. Polymeropoulos, MD, president and CEO of Vanda, said in the release.

The company expects to begin study enrollment before the end of the year, with results available in 2021.